CHAUMBURG, Ill., and SOPHIA ANTIPOLIS, France — Galderma, whose brands include Cetaphil, and The American Academy of Dermatology have announced the creation of the American Academy of Dermatology Translational Biotechnology Fellowship.
The new fellowship will offer a dermatologist the opportunity to work in drug development and translational medical research at Galderma's R&D facility located in Sophia Antipolis, France. This learning opportunity will allow the physician to advance science and explore career options within a pharmaceutical industry setting.
Galderma will host two one-year fellowships, one beginning in fall 2013 and one beginning in fall 2014 at Sophia Antipolis, a corporate-funded facility dedicated to skin research.
The fellow will gain knowledge of the specific requirements of drug development and be given opportunities for exploration within the pharmaceutical industry environment. The AAD will provide the selected candidate a stipend to cover his or her costs during the term of the fellowship, and Galderma will host and provide necessary resources to support and mentor the Fellow.
Preference will be given to candidates who are in their last year of residency in an accredited American College of Graduate Medical Education dermatology residency program. Candidates must be a physician member of the Academy who will have satisfactorily completed a residency no more than three years before the planned start date. Candidates must be interested in pursuing research and exploring careers in an industry setting. The AAD will review fellowship applications and recommend one candidate each year the fellowship is offered.
The application for the fall 2013 fellowship is available at www.aad.org/biotechfellowship. Submissions will be accepted through May 31. The 2013 recipient will be notified in July. The application for the fall 2014 fellowship will be available on the website in mid-June 2013. The 2014 recipient will be notified in December 2013.